Du Lihong, Fang Chenglong, Huang Biqing, Zeng Xiaofeng, Li Jing, Tian Xinping
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100006, China.
National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing 100006, China.
Int J Mol Sci. 2025 Mar 22;26(7):2881. doi: 10.3390/ijms26072881.
Our previous work identified several differentially expressed miRNAs (DEmiRNAs) in plasma exosomes from Takayasu's arteritis (TAK) patients. This study aimed to validate these findings and explore the correlation between DEmiRNAs and clinical parameters in untreated TAK. Plasma exosomes were isolated from 30 untreated TAK patients and 20 healthy controls. qPCR was used to quantify miR-34a-5p, miR-143-3p, miR-22-3p, miR-200c-3p, and miR-21-5p expression. Correlations between miRNA levels, clinical data, inflammation markers, and T helper cell frequencies were analyzed. The target genes of validated DEmiRNAs were identified using mirDIP, and pathway enrichment analysis was performed using GO/KEGG. The effect of validated DEmiRNAs on the MAPK pathway and proliferation in human aortic endothelial cells (HAECs) was investigated in vitro. Only miR-200c-3p expression was validated as significantly downregulated in plasma exosomes from untreated TAK patients. Lower miR-200c-3p levels correlated negatively with ITAS-2010 scores and were associated with relapsed disease. MiR-200c-3p levels also negatively correlated with circulating Th17.1 cell frequencies. In vitro, the TAK exosome treatment activated ERK1/2 and JNK pathways and promoted HAEC proliferation, which was inhibited by the miR-200c-3p mimic. The pathway enrichment analysis showed that the MAPK pathway may be involved. This study confirms the reduced miR-200c-3p expression in plasma exosomes from TAK patients, suggesting its potential as a biomarker for vascular inflammation. MiR-200c-3p may exert protective effects in TAK by suppressing MAPK pathway activation and EC proliferation.
我们之前的研究在大动脉炎(TAK)患者的血浆外泌体中鉴定出了几种差异表达的微小RNA(DEmiRNAs)。本研究旨在验证这些发现,并探讨未治疗TAK中DEmiRNAs与临床参数之间的相关性。从30例未治疗的TAK患者和20名健康对照中分离出血浆外泌体。采用qPCR定量miR-34a-5p、miR-143-3p、miR-22-3p、miR-200c-3p和miR-21-5p的表达。分析了miRNA水平、临床数据、炎症标志物和T辅助细胞频率之间的相关性。使用mirDIP鉴定已验证的DEmiRNAs的靶基因,并使用GO/KEGG进行通路富集分析。在体外研究了已验证的DEmiRNAs对人主动脉内皮细胞(HAECs)中MAPK通路和增殖的影响。仅miR-200c-3p的表达在未治疗TAK患者的血浆外泌体中被验证为显著下调。较低的miR-200c-3p水平与ITAS-2010评分呈负相关,并与疾病复发相关。miR-200c-3p水平也与循环Th17.1细胞频率呈负相关。在体外,TAK外泌体处理激活了ERK1/2和JNK通路并促进了HAEC增殖,而miR-200c-3p模拟物可抑制这种增殖。通路富集分析表明MAPK通路可能参与其中。本研究证实了TAK患者血浆外泌体中miR-200c-3p表达降低,表明其作为血管炎症生物标志物的潜力。miR-200c-3p可能通过抑制MAPK通路激活和内皮细胞增殖在TAK中发挥保护作用。